Among them, activating mutation of epidermal growth factor receptor (EGFR) drives the progression of NSCLC, and tumors with EGFR activating mutations (such as exon 19 deletion or exon 21 L858A mutation) are particularly sensitive to the treatment of EGFR tyrosine kinase inhibitors (TKIs) [5]. Here, EGFR is linked to non-small cell lung carcinoma.